VIR BIOTECHNOLOGY INC (VIR)
Sector: Health Care
2026 Annual Meeting Analysis
VIR BIOTECHNOLOGY INC · Meeting: May 26, 2026
Directors FOR
1
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
The 3-year TSR trigger fires because VIR underperformed its peer group median by 24.4 percentage points (exceeding the 20pp threshold for companies with negative absolute returns), but the 5-year check shows VIR's underperformance versus the same peer median is only 2.4 percentage points — well below the 20pp threshold — meaning the longer track record is adequate and the policy calls for upgrading the vote to FOR.
The proxy discloses that Ms. Napolitano attended only 72% of board and committee meetings in 2025, which falls below the 75% minimum attendance standard required by the voting policy, warranting a vote against her re-election.
For Analysis
The 3-year TSR trigger fires for Dr. Sigal (director since 2020) just as it does for Mr. More, but the 5-year relative performance gap of only 2.4 percentage points versus the peer median falls well below the 20pp policy threshold, indicating the recent underperformance is not representative of the full tenure period, so the policy calls for a FOR vote.
Of the three Class I nominees, Ms. Napolitano receives an AGAINST vote solely because she attended only 72% of board and committee meetings in 2025, falling below the 75% attendance threshold. Both Mr. More and Dr. Sigal trigger the 3-year TSR underperformance screen (VIR underperformed the company-disclosed peer group median by 24.4 percentage points, exceeding the 20-percentage-point threshold applicable to companies with negative absolute 3-year returns), but both are rescued by the 5-year mitigant — over the five-year horizon VIR trailed the peer median by only 2.4 percentage points, well inside the threshold, indicating the underperformance is a recent development against an otherwise adequate longer-term track record.
Say on Pay
✓ FORCEO
Marianne De Backer, M.Sc., Ph.D., MBA
Total Comp
$7,834,045
Prior Support
96%%
The prior year Say on Pay vote received approximately 96% shareholder support, well above the 70% threshold, signaling broad satisfaction with the program. The CEO's reported total compensation of $7,834,045 is reasonable for a clinical-stage biotech CEO at a $1.6 billion company, and the majority of pay is at-risk through stock options (which only gain value if the stock price rises) and performance-based annual bonuses tied to a transparent scorecard — in 2025 the corporate attainment score of 125% reflects genuine clinical and business development milestones. The company also maintains multiple clawback policies and equity ownership guidelines, and no special off-cycle awards were made in 2025, all of which support a FOR vote.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
9 yrs
Audit Fees
$2,212,000
Non-Audit Fees
$0
Ernst & Young LLP charged $2,212,000 in audit fees for fiscal year 2025 and zero in non-audit fees, giving a non-audit fee ratio of 0% — well below the 50% threshold that would raise independence concerns. EY has audited VIR since 2017 (approximately 9 years), which is comfortably below the 25-year tenure threshold. No material restatements were identified. EY is a Big 4 firm appropriate for a $1.6 billion market cap company.
Overall Assessment
The 2026 VIR Biotechnology annual meeting presents three standard proposals: the voting policy supports ratification of Ernst & Young (clean fee structure, appropriate tenure) and advisory approval of executive compensation (strong prior-year support, meaningful at-risk pay structure), but votes AGAINST Janet Napolitano's re-election due to below-threshold board attendance (72%) while supporting both Mr. More and Dr. Sigal despite a 3-year TSR trigger firing, because the 5-year relative performance check shows adequate longer-term results that rescue both directors under the policy's mitigant rule.
Compensation Peer Group
17 companies disclosed in 2026 proxy filing